Halozyme Therapeutics (HALO) Appoints New COO

September 1, 2016 9:01 AM EDT

Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.

Halozyme Therapeutics, Inc. (NASDAQ: HALO) named biotech veteran Mark J. Gergen as senior vice president and chief operating officer, reporting to Dr. Helen Torley, president and chief executive officer.

Gergen will be responsible for corporate development, including the management of Halozyme's proprietary ENHANZEâ„¢ platform collaborations and overseeing the global product teams responsible for planning the development and commercialization of Halozyme's oncology pipeline, including clinical operations and clinical collaborations.

"Mark brings a wealth of business development and operational experience that will be essential as we execute our plan to accelerate growth of the ENHANZE platform and develop and commercialize multiple oncology drugs," said Dr. Torley. "With more than 20 years of healthcare and biotech experience, he will be a strong addition to our management team as we execute our growth strategy."

Gergen joins Halozyme most recently from Mirati Therapeutics, an oncology biotech, where he was executive vice president and chief operating officer reporting to the CEO and responsible for the strategy, corporate development, finance, investor relations, human resources, information technology and legal functions. He executed multiple successful partnerships, collaborations and licensing agreements.

Before Mirati, he spent 7 years at Amylin Pharmaceuticals as a member of the executive committee reporting to the CEO, where he led corporate development and alliances.

"I am excited to join the Halozyme team as the company continues to execute against its business objectives and corporate strategy," said Gergen. "The advancements in the oncology pipeline together with the opportunity to grow the proprietary ENHANZE platform create a unique opportunity to build significant shareholder value."

Prior to Amylin, Gergen held senior management roles for Cardionet and Advanced Tissue Sciences, as well as the large group purchasing organization, Premier, and medical device pioneer, Medtronic. He earned his B.A. in Business Administration from Minot State University in North Dakota and J.D. from the University of Minnesota Law School.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

Management Changes, Management Comments

Add Your Comment